T-E Pharma has developed a proprietary and innovative “T-E Pharmaceuticals” platform, anchored by a core “multi-arm linker” technology. This platform extends into three specialized sub-platforms: the “fatty acid bundle”, the “cytotoxic drug bundle”, and the chelator bundle.
Within this framework, Immunwork is dedicated to advancing the “fatty acid bundle” technology and its associated long-acting therapeutics, alongside other T-E pharmaceutical candidates.
Meanwhile, T-E Meds focuses on harnessing the “cytotoxic drug bundle” and “chelator bundle” sub-platforms to build a diverse portfolio of ADC and ARC products.
